Related content

Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine

By Pitako J.   Haas P.   Bosch J.   Müller-Berndorff H.   Kündgen A.   Germing U.   Wijermans P.   Lübbert M.  

Annals of Hematology, Vol. 84, Iss. 1, 2005-12 ,pp. : 25-31

Springer Publishing Company

Access to resources Recommend Favorite

The myelodysplastic syndromes: Diagnosis, molecular biology and risk assessment

By Bennett John   Komrokji Rami  

Hematology, Vol. 10, Iss. 1, 2005-09 ,pp. : 258-269

Maney Publishing

Access to resources Recommend Favorite

Is it time for 5-azacytidine combinations in high-risk myelodysplastic syndrome patients?

By Park Sophie  

Expert Review of Hematology, Vol. 6, Iss. 1, 2013-02 ,pp. : 39-42

Informa Healthcare

Access to resources Recommend Favorite

Alcohol consumption and risk of myelodysplastic syndromes: A metaanalysis of epidemiological studies

By                

Molecular and Clinical Oncology, Vol. 2, Iss. 6, 2014-01 ,pp. : 1115-1120

Spandidos Publications

Access to resources Recommend Favorite

Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia

By Anargyrou Konstantinos   Vaiopoulos George   Terpos Evangelos   Tsironi Maria   Konstantopoulos Konstantinos   Samarkos Michael   Meletis John  

Haematologia, Vol. 32, Iss. 2, 2002-06 ,pp. : 169-173

VSP

Access to resources Recommend Favorite